Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index; 27 of the 135 sources its claims cite were checked for support.
Abstract
Colorectal cancer (CRC) is one of the most common malignant cancers and its incidence is steadily rising particularly in young patients. While screening measures and the widespread availability of surgical treatment have led to an impressive improvement of prognosis within the overall CRC population, patients with metastatic CRC still face 5-year survival rates of around 10–25%. Despite continuous development of new systemic treatment strategies that include cytotoxic chemotherapy and targeted therapy, most patients with metastatic CRC eventually progress. However, a small proportion of patients with mismatch repair-deficient or microsatellite unstable CRC responds exceptionally well to treatment with immune checkpoint inhibitors, thereby proving that CRC is in principle amenable to immunotherapy and showing that long-term disease stabilisation can be achieved even in metastasised stages. However, the reasons for the lack of response to immunotherapy in the vast majority of CRC cases remain to be elucidated. Yet, recent evidence suggests that the tumour stroma, which includes non-immune cells in the colorectal tumour microenvironment, mediates immunosuppressive mechanisms that prevent effective immunotherapy. These findings open new avenues for the development of advanced immunotherapies for CRC. In this review, we summarise major developments in the systemic therapy of CRC within the last couple of decades, provide an overview of emerging and soon-to-be implemented therapeutic strategies and present concepts from clinical and preclinical research to manipulate tumour cells and the tumour stroma to sensitise microsatellite stable colorectal tumours to immunotherapy.
Overview
CoChat Summary
TL;DR
This review summarizes systemic treatment of metastatic colorectal cancer (mCRC), emphasizing that pMMR/MSS tumors remain largely resistant to immunotherapy while dMMR/MSI-H tumors can achieve durable responses to immune checkpoint blockade (ICB). It highlights emerging biomarker-driven targeted therapies, antibody-drug conjugates, and tumor microenvironment/stroma-directed strategies to sensitize MSS/pMMR mCRC to immunotherapy.
Key findings
- mCRC prognosis remains poor: 5-year survival is around 10–25%; about 20–25% of CRC cases are metastatic at diagnosis; half of patients with mCRC die within approximately 30 months; global CRC-related deaths are projected to rise from around 915,000 in 2020 to over 1.5 million in 2040. Chemotherapy improved overall survival from approximately 6 months in untreated historical cohorts to 16–20 months for FOLFOX or FOLFIRI, while surgical resection of metastases is feasible in only 10–30% of patients.
- dMMR/MSI-H CRC, around 3–15% of cases, is highly immunogenic and responds to ICB; a 2015 phase II trial showed durable responses in more than 50% of dMMR/MSI-H patients, and Keynote-177 established pembrolizumab as first-line standard of care. CheckMate 8HW confirmed strong efficacy of dual ipilimumab plus nivolumab, but up to 50% of patients on single-agent ICB and up to 25% on double-agent ICB progress within the first 6 months.
- pMMR/MSS tumors, approximately 90% of CRC, are immune-cold and do not respond to ICB; the tumor stroma, including cancer-associated fibroblasts, TGF-β, immune exclusion, and MHC-I loss, mediates immunosuppression. TME-based biomarkers such as the immunoscore and IS-IC may select responders; in the FFCD 1703-POCHI trial, preliminary 10-month PFS was almost 70% in patients with high tumorous leucocyte infiltration.
- Emerging targeted and antibody-drug conjugate data include KRAS p.G12C in approximately 3% of CRC, with sotorasib plus panitumumab showing median PFS of 5.6 vs 2.2 months, and adagrasib plus cetuximab showing ORR 34%, DCR 85.1%, mPFS 6.9 months, and mOS 15.9 months. ERBB2 amplification is about 3% overall and 5–7% in left-sided RAS/BRAF wild-type tumors; MOUNTAINEER reported tucatinib plus trastuzumab ORR 38.1%, mPFS 8.2 months, and mOS 24.1 months, while DESTINY-CRC02 reported T-DXd ORR 37.8% at 5.4 mg/kg and 27.5% at 6.4 mg/kg.
Methods
- Narrative review of clinical and preclinical literature on systemic therapy for mCRC, covering current standard of care, emerging biomarker-driven therapies, ICB, antibody-drug conjugates, bispecific antibodies, and TME/stroma-targeted strategies.
- Synthesizes published trial results and ongoing clinical trials, with tables listing NCT numbers, phases, patient populations, biomarker stratification, treatments, and outcomes.
- No systematic review methodology, search strategy, or meta-analysis is reported.
Limitations
- Stated: treatment standards are region- and country-specific; survival data in Figure 1 derive from selected trial-eligible patients and should not be used for general population prediction; trials mostly include CRC liver metastasis and underrepresent peritoneal metastasis.
- Stated: clinical translation of TGF-β inhibition plus immunotherapy has largely failed despite preclinical promise; IS-IC needs further validation in different cohorts; CAR-T and adoptive cell therapies have so far been unsuccessful in solid malignancies like CRC.
- Evident: as a narrative review, it lacks a formal systematic search and quality appraisal and relies on selected literature and ongoing trial registrations; many cited emerging approaches are early-phase or ongoing without mature overall survival data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
19 Valid · 3 Not valid · 92 Not checked · 16 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Preclinical and clinical data suggest that resistance to KRAS p.G12C inhibition is dependent on receptor tyrosine kinase activity, especially epidermal growth factor receptor (EGFR)-signalling.29 31 32”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Emerging biomarker-driven therapeutic concepts for mCRC
What the sources say
- Partly supportedcites [29] sourceExperimental — accuracy not yet measured
The Results (Mechanisms of Acquired Resistance to Adagrasib; page unavailable) identify alterations in the RTK–RAS–MAPK pathway among patients with acquired resistance, including one EGFR mutation. The Discussion reports such alterations in 14 of 38 patients, but also describes KRAS mutations and histologic transformation as resistance mechanisms. This supports an RTK-pathway role in some cases, not a general dependence on RTK activity or a special predominance of EGFR signaling. (LLM, conf=0.88)
- Partly supportedcites [31] sourceExperimental — accuracy not yet measured
The Introduction (p. 4) says EGFR reactivation restricts KRAS G12C inhibitor efficacy in colorectal cancer models, and the Discussion (p. 7) links those findings to lower clinical response rates in colorectal cancer. The paper does not show clinically that EGFR signalling causes resistance, and it distinguishes colorectal from lung cancer rather than establishing EGFR dependence across all KRAS G12C cancers. (LLM, conf=0.86)
- Disputedcites [32] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that mutations downstream of RAS suggest MAPK reactivation alone may be sufficient to drive resistance in some KRASG12C cancers. It also describes resistance through a KRAS mutation that alters inhibitor binding. These mechanisms contradict the claim that resistance depends on receptor tyrosine kinase activity, particularly EGFR signalling. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The first biological agents targeting the epidermal growth factor receptor (EGFR) and VEGF (receptor) (VEGF(R)) further improved systemic treatment;21 22”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Current standard of care for treatment of metastasised colorectal cancer
What the sources say
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
Our copy supports only the EGFR half of the claim: the Background and Results sections state that cetuximab, a monoclonal antibody that specifically blocks EGFR, had clinical activity in irinotecan-refractory metastatic colorectal cancer, with a higher response rate (22.9% vs 10.8%, P=0.007) and longer time to progression (4.1 vs 1.5 months, P<0.001) than cetuximab alone. The VEGF(Receptor)-targeted agent half is not supported: searches for VEGF, vascular endothelial growth factor, bevacizumab and angiogenesis returned no passage in which this paper addresses anti-VEGF therapy (angiogenesis appears only as one process downstream of EGFR signaling, and in the title of a cited radiation-biology reference). The paper also does not make the broader historical framing ('the first biological agents ... further improved systemic treatment'); its benefit claims are bounded to heavily pretreated, EGFR-expressing, irinotecan-refractory disease. (LLM, conf=0.78)
- Not checked yetcites [22] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the prognostic relevance of ERBB2 amplification itself in mCRC remains controversial.42 43 45”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Emerging biomarker-driven therapeutic concepts for mCRC
What the sources say
- Not checked yetcites [42] Sawada, 2018, Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer, Clin Colorectal Cancer
- Not checked yetcites [43] Raghav, 2019, Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer, JCO Precis Oncol source
- Partly supportedcites [45] Richman, 2016, HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials, J Pathol sourceExperimental — accuracy not yet measured
Richman et al. (2016) do supply material consistent with unsettled prognostic significance in stage IV disease — the Discussion states that in FOCUS/PICCOLO 'we did not find an association between HER2 expression and PFS or OS... Due to the rarity of HER2 overexpression, the power to detect a modest effect on outcome is low, but we can exclude a strong effect,' and the Discussion reports Martin et al.'s (ref 30) finding of inferior PFS/OS in HER2-amplified KRAS WT patients while noting 'the small sample size limits interpretation of this result.' However, the paper does not characterise the issue as controversial: its stated conclusion is that 'HER2 overexpression is not a prognostic biomarker' and that its negative survival result 'agrees with two previous studies, which failed to detect a prognostic biomarker effect for HER2 10, 13.' A further specificity gap: the outcome analyses (Results, 'HER2 and recurrence rate, PFS and OS analysis'; Abstract) contrasted IHC-defined strong HER2 overexpression with no overexpression, not FISH/microarray-defined ERBB2 amplification per se, so the 'amplification itself' part of the claim is not what this source tested. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A novel interesting approach was recently published, identifying local enrichment of cytotoxic lymphocytes with an interferon-high immunophenotype that induces antigen-presentation in adjacent macrophages and tumour cells as a positive response predictor in subsets of dMMR/MSI-H but also pMMR/MSS CRC.108”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Immune checkpoint blockade in MSI-H/dMMR metastatic colorectal cancer
What the sources say
- Supportedcites [108] Acha-Sagredo, 2025, A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer, Cancer Cell source
The SUMMARY (p. 2) states that an interferon-high immunophenotype locally enriched in cytotoxic lymphocytes and antigen-presenting macrophages is required for response, that it is not exclusive to dMMR CRC but comprises a subset of pMMR CRCs, and that interferon-producing cytotoxic T cells induce overexpression of antigen presentation (including CD74) in adjacent macrophages and tumor cells. The mechanism is directly evidenced in 'T cell proximity induces CD74 upregulation in TAMs and tumor cells' (pp. 6-7), and the clinical claim in both subtypes is carried by 'High CD74 expression is associated with response to anti-PD-1 ICI in dMMR CRC' (p. 9) and 'High CD74 SPS predicts clinical benefit in ICI-treated pMMR CRC patients' (p. 11), where the pMMR benefit is measured as progression-free survival in ICI-combination trials (CAMILLA, AtezoTRIBE). The Article Cell discussion (p. 13) additionally notes ~20% of pMMR CRCs carry the IFN-high IP. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Two of these subtypes, CMS1 and CMS4, are characterised by a pronounced activation of the TME.”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Strategies to overcome resistance of pMMR/MSS colorectal cancer to immunotherapy
What the sources say
- Supportedcites [121] source
In Results, under “Biological characterization of the consensus molecular subtypes,” CMS1 is described as having a diffuse immune infiltrate and strong immune-evasion activity. The same section describes CMS4 as having stromal infiltration and activation of angiogenesis, matrix-remodeling, and inflammatory pathways. These findings support the characterization of both subtypes as having pronounced tumour-microenvironment activity. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 5 with their cited sources checked
Create a free account to see all 130 claims and to verify the 108 references still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 53
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Emerging biomarker-driven therapeutic concepts for mCRC
“NCT06105021 | I/II | Advanced or metastatic solid tumours (n=100) | KRAS G12C mutation and positive for HLA-A*11:01”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Emerging biomarker-driven therapeutic concepts for mCRC
“The cells are engineered and grown to recognise the KRAS G12V protein on the cell surface of cancer cells.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Antibody-drug conjugates
“Table 5 Ongoing clinical trials on antibody drug conjugates and peptide drug conjugates excluding ERBB2/HER2 targeted approaches”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Antibody-drug conjugates
“NCT05493683 | II | Advanced or metastatic CRC (n=29) | Her2 overexpression | Disitamab vedotin+tislelizumab (anti-PD-1) | Her2”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Emerging biomarker-driven therapeutic concepts for mCRC
“MOUNTAINEER-03 (NCT0525365)”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Emerging biomarker-driven therapeutic concepts for mCRC
“NCT05253651 | III | Advanced or metastatic CRC (n=400) | Her2 positive,RAS wild-type | Tucatinib+trastuzumab + mFOLFOX vs mFOLFOX+bevacizumab”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Antibody-drug conjugates
“actinium-255”
§ Current and emerging concepts for systemic treatment of metastatic colorectal cancer > Introduction > Antibody-drug conjugates
“(225Ac)”
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 2×
“121 122 In colorectal liver metastases, transcriptomic classification using a modified CMS classifier resulted in an enrichment of the CMS2 and CMS4 subtypes compared with primary tumours, 123 suggesting that the tumour stroma represents an attractive therapeutic target in mCRC to revert…”
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271 · cited 3×
“79 Further, patient stratification and biomarker identification are crucial to select patients who would benefit from ADC treatment 59 as antigens are expressed differently in human tumours compared with preclinical animal models with respect to orientation, polarity and cell surface expression.”
Research works printed but not linked: 3
- 10.1002/1097-0142(19900501)65:9&2091::aid-cncr2820650934 · doi:10.1002/1097-0142(19900501)65:9&2091::aid-cncr2820650934
- Alese, 2023, Update on Emerging Therapies for Advanced Colorectal Cancer, Am Soc Clin Oncol Educ Book, 43, 10.1200/edbk_389574 · DOI
- 10.1200/jco.22.01690 · DOI · Paper page
Cited by
Agüera-Sánchez, A., Ros, E. P., Martínez‐Martínez, I., & García-Molina, F. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010048 · Cited by 9
“Ongoing trials are exploring whether certain immunoscore or tumor microenvironment features in MSS CRC could predict benefit from emerging immunotherapy combinations—e.g., adding VEGF inhibitors or novel immunomodulators to overcome resistance—[128,129], but such biomarkers remain exploratory.”
Marafini, I., Frascatani, R., Colella, M., Cristofaro, E. D., & Monteleone, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682223 · Cited by 8
Nardone, V., Patanè, V., Marinelli, L., D’Ambrosio, L., Tufo, S. D., Chiara, M. D., Brunese, M. C., Rubini, D., Grassi, R., Russo, A., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15222914 · Cited by 5
Yang, F., Wang, M., Hu, S., Guan, X., Zhao, K., Zhou, Y., Yao, H., Zhang, T., Li, L., Jing-yuan, G., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02675-8 · Cited by 5
“4 Therefore, elucidating the underlying mechanisms by which CRC cells inhibit the immune microenvironment and evade immune surveillance, along with developing these novel target-based strategies, represents a critical focus for enhancing progression-free survival in patients with various types of…”
The dawn of immunotherapy in mismatch repair proficient colorectal cancer
Rasschaert, G., & Tejpar, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02113-0 · Cited by 3
Metadata
- Authors
- Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R.
- Affiliations
- Goethe University Frankfurt (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
- Corresponding author
- Greten, Florian R
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2025-10-05
- Volume
- 74
- Issue
- 12
- Pages
- 2070-2095
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC12703343
- OpenAlex
- W4414833677
- Semantic Scholar
- 5de38dc074c66ec05aeca1da51cb78c1725d9acc
- Cited by
- 39
- References
- 167
- Citations by year
- 2026: 34 · 2025: 5
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gut (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- Funders
- H2020 European Research Council (101021078)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- metastatic colorectal cancer, systemic therapy, immunotherapy, immune checkpoint inhibitors, mismatch repair deficiency, microsatellite instability, tumor microenvironment, tumor stroma, immunosuppression, chemotherapy, targeted therapy, immunotherapy resistance
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Immunotherapy, Neoplasm Metastasis, Colorectal Neoplasms, Microsatellite Instability, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and emerging concepts for systemic treatment of metastatic colorectal cancer. https://app.cochat.ai/papers/10.1136/gutjnl-2025-335412
- The paper
- Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025). Current and emerging concepts for systemic treatment of metastatic colorectal cancer. Gut. https://doi.org/10.1136/gutjnl-2025-335412
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.